get_earnings| Q3 FY26 | YoY | |
|---|---|---|
| Revenue | $41.2B | +26.1% |
| Net income | $162.0M | -16.9% |
| Op income | $75.0M | -81.3% |
| EPS (dil.) | $1.331 | – |
| EPS (basic) | $1.35 | -16.7% |
| Op margin | 0.2% | -1.1pp |
| Net margin | 0.4% | -0.2pp |
| Metric | Value | Period | Specificity | vs Prior |
|---|---|---|---|---|
| membership | up | 2027 | directional | New |
| Stars performance | top quartile | BY 2029 | directional | New |
| Part D trend | 14% to 15% | 2027 | wide_range | New |
| medical cost trend | 8% to 9% | 2027 | tight_range | New |
LLM-extracted from the earnings release; unverified.
| Q2 FY26 | YoY | 6M FY26 | |
|---|---|---|---|
| Revenue | $40.9B | +26.2% | – |
| Net income | $693.0M | +27.6% | – |
| Op income | $1.4B | – | – |
| EPS (dil.) | $5.731 | +27.1% | $15.55 |
| EPS (basic) | $5.78 | +27.9% | $15.64 |
| Op margin | 3.3% | -0.1pp | |
| Net margin | 1.7% | +0.0pp |
| Q1 FY26 | YoY | |
|---|---|---|
| Revenue | $39.6B | +23.5% |
| Net income | $1.2B | -4.7% |
| Op income | $1.8B | -12.9% |
| EPS (dil.) | $9.831 | -4.6% |
| EPS (basic) | $9.85 | -4.5% |
| Op margin | 10.2% | – |
| Net margin | 3.0% | -0.9pp |
| Q4 FY25 | YoY | FY25 | |
|---|---|---|---|
| Revenue | $32.5B | +11.3% | $129.7B |
| Net income | – | – | – |
| Op income | – | – | – |
| EPS (dil.) | $-6.61 | – | – |
| EPS (basic) | – | – | – |
| Q3 FY25 | YoY | 9M FY25 | |
|---|---|---|---|
| Revenue | $32.6B | +11.1% | $97.1B |
| Net income | – | – | – |
| Op income | – | – | – |
| EPS (dil.) | $1.62 | -59.3% | $16.43 |
| EPS (basic) | – | – | – |
| Filing | Date | Period | Sections | Tables |
|---|---|---|---|---|
| 8-K | 2026-11-09 | – | 3 | 0 |
| 10-Q | 2026-11-06 | – | 31 | 42 |
| 8-K | 2026-11-06 | Q3 2026 | 13 | 0 |
| 8-K | 2026-10-13 | – | 3 | 0 |
| 8-K | 2026-10-09 | – | 1 | 0 |
| 8-K | 2026-09-01 | – | 1 | 0 |
| 10-Q | 2026-07-29 | – | 31 | 45 |
| 8-K | 2026-07-29 | – | 3 | 0 |
| 8-K | 2026-07-29 | Q2 2026 | 12 | 0 |
| 8-K | 2026-05-19 | – | 2 | 0 |
Showing the latest 10 of 66 — the full set is in the API.